Actively Recruiting
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Led by Brigham and Women's Hospital · Updated on 2025-02-05
20
Participants Needed
2
Research Sites
191 weeks
Total Duration
On this page
Sponsors
B
Brigham and Women's Hospital
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This pilot study will assess the feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in ovarian, fallopian tube, and primary peritoneal cancer. The name of the study intervention involved in this study is: -implantable microdevice
CONDITIONS
Official Title
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have suspected or confirmed advanced stage (III-IV) ovarian, fallopian tube, or peritoneal cancer.
- Participants must fit into one of four clinical groups related to diagnosis and surgical candidacy.
- Participants must be 18 years of age or older.
- Participants must be medically stable to undergo percutaneous procedures and surgery.
- Participants must have laboratory results within specified limits before microdevice placement.
- Participants must be evaluated and approved by surgical and medical gynecologic oncologists.
- Participants must have a recent CT scan showing disease extent and a suitable tumor for microdevice placement.
- Participants must have sufficient tumor volume for implantation and safe removal during surgery.
- Participants must understand and be willing to sign informed consent.
- Participants must agree to research-related genetic sequencing and data sharing.
You will not qualify if you...
- Participants with uncontrolled illnesses such as active infection, symptomatic heart failure, unstable angina, arrhythmia, or psychiatric/social conditions limiting safety.
- Pregnant women due to imaging radiation and biopsy risks.
- Participants with uncorrectable bleeding or coagulation disorders increasing biopsy or surgery risk.
- Participants with significant risk factors preventing safe cessation of anticoagulation medications, except those only taking low-dose aspirin.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Actively Recruiting
2
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
Research Team
E
Elizabeth Stover, MD, PhD
CONTACT
M
Madeline Polak, BS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here